Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Entelos has announced that the US Patent and Trademark Office has granted patent for new technology, which helps researchers to screen novel compounds more rapidly and efficiently during preclinical studies for cholestasis, a specific type of drug-induced liver damage.
Subscribe to our email newsletter
This new patent relates to a method of testing a drug or novel compound to determine its propensity for inducing cholestasis, a common toxic side effect of certain drugs, by looking at its impact on a set of indicator genes, or biomarkers.
This biomarker set is one of dozens from the company’s proprietary library of Drug Signatures, which have been derived from DrugMatrix, the reference database linking gene expression profiles of over 630 drugs to results from traditional preclinical pharmacology, safety, and toxicity tests.
James Karis, president and CEO of Entelos, said: “We are pleased to add this new patent to our growing portfolio of patents that strengthen our leadership position in both disease simulation and predictive technologies focused on safety and toxicity testing.”